IN164232B - - Google Patents

Info

Publication number
IN164232B
IN164232B IN300/BOM/85A IN300BO1985A IN164232B IN 164232 B IN164232 B IN 164232B IN 300BO1985 A IN300BO1985 A IN 300BO1985A IN 164232 B IN164232 B IN 164232B
Authority
IN
India
Prior art keywords
alkyl
aryl
cycloalkyl
represents hydrogen
integer
Prior art date
Application number
IN300/BOM/85A
Other languages
English (en)
Inventor
Samba Laxminarayan Kattige
Ramchandra Ganapati Naik
Aftab Dawoodbhai Lakdawala
Alihussein Nomanbha Dohadwalla
Souza Neol John De
Richard Helmut Rupp
Original Assignee
Hoechst India
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst India filed Critical Hoechst India
Publication of IN164232B publication Critical patent/IN164232B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/42Oxygen atoms attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
IN300/BOM/85A 1986-04-11 1985-10-31 IN164232B (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863612337 DE3612337A1 (de) 1986-04-11 1986-04-11 4h-1-benzopyran-4-on-derivate, ein verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
IN164232B true IN164232B (ja) 1989-02-04

Family

ID=6298535

Family Applications (1)

Application Number Title Priority Date Filing Date
IN300/BOM/85A IN164232B (ja) 1986-04-11 1985-10-31

Country Status (16)

Country Link
US (1) US4900727A (ja)
EP (1) EP0241003B1 (ja)
JP (1) JPH0686446B2 (ja)
KR (1) KR950009861B1 (ja)
AT (2) ATE95519T1 (ja)
AU (1) AU602891B2 (ja)
CA (1) CA1332238C (ja)
DE (2) DE3612337A1 (ja)
DK (1) DK169760B1 (ja)
ES (1) ES2060582T3 (ja)
HK (1) HK1006021A1 (ja)
IE (1) IE62244B1 (ja)
IL (1) IL82149A (ja)
IN (1) IN164232B (ja)
PT (1) PT84654B (ja)
ZA (1) ZA872555B (ja)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5278174A (en) * 1990-06-04 1994-01-11 Scios Nova, Inc. Sigma binding site agents
EP0508347A1 (en) * 1991-04-10 1992-10-14 Hoechst Aktiengesellschaft 5,7-Dihydroxy-2-methyl-8-[4-(3-hydroxy-1-(1-propyl)) piperidinyl]-4H-1-benzopyran-4-one, its preparation and its use
US6476011B1 (en) 1991-08-28 2002-11-05 Sterix Limited Methods for introducing an estrogenic compound
GB9604709D0 (en) * 1996-03-05 1996-05-01 Imperial College A compound
US6011024A (en) 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
US6903084B2 (en) 1991-08-29 2005-06-07 Sterix Limited Steroid sulphatase inhibitors
SK280617B6 (sk) * 1992-01-16 2000-05-16 Hoechst Aktiengesellschaft Arylcykloalkylové deriváty, spôsob ich prípravy, f
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US6506792B1 (en) 1997-03-04 2003-01-14 Sterix Limited Compounds that inhibit oestrone sulphatase and/or aromatase and methods for making and using
US20060241173A1 (en) * 1996-02-16 2006-10-26 Sterix Ltd. Compound
US6087366A (en) * 1996-03-07 2000-07-11 The Trustees Of Columbia University In The City Of New York Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death
US5849733A (en) * 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US5908934A (en) * 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
DE19802449A1 (de) * 1998-01-23 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von (-)cis-3-Hydroxy-1-methyl-4-(2,4,6-trimethoxypyhenyl)-piperidin
GB9807779D0 (en) * 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
US6399633B1 (en) * 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (de) * 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US6576647B2 (en) 2000-01-18 2003-06-10 Aventis Pharmaceuticals Inc. Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one
JP2003520797A (ja) * 2000-01-18 2003-07-08 アベンテイス・フアーマシユーチカルズ・インコーポレーテツド (−)−シス−2−(2−クロロフェニル)−5,7−ジヒドロキシ−8[4R−(3S−ヒドロキシ−1−メチル)ピペリジニル]−4H−1−ベンゾピラン−4−オンの偽多形体(pseudopolymorph)
US6821990B2 (en) 2000-01-18 2004-11-23 Aventis Pharma Deutschland Gmbh Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5, 7-dihydroxy-8 [4R-(3S-hydroxy-1-M ethyl) piperidinyl]-4H-1-benzopyran-4-one
SI1252155T1 (en) * 2000-01-18 2005-06-30 Aventis Pharmaceuticals Inc. Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8- (4r-(3s-hydroxy-1-methyl)piperidinyl)-4h-1-benzopyran-4-one
FR2805538B1 (fr) * 2000-02-29 2006-08-04 Hoechst Marion Roussel Inc Nouveaux derives de flavones, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
KR100423899B1 (ko) 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
RU2308454C9 (ru) 2002-04-17 2008-05-10 Цитокинетикс, Инк. Соединения, композиции на их основе и способы их использования
US7271193B2 (en) * 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
US7915301B2 (en) * 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
US7884127B2 (en) * 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
DE60326248D1 (de) * 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
EP1554265A4 (en) * 2002-09-13 2008-05-07 Cytokinetics Inc COMPOSITIONS, COMPOSITIONS AND M THODES
EP1670456A2 (en) * 2003-10-06 2006-06-21 Cytokinetics, Inc. Compounds, compositions and methods
DE602004024115D1 (de) * 2003-12-09 2009-12-24 Us Gov Health & Human Serv Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen
EP1699477A2 (en) * 2003-12-11 2006-09-13 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
MX2008016398A (es) 2006-06-21 2009-01-21 Piramal Life Sciences Ltd Compuestos enantiomericamente puros novedosos para el tratamiento de trastornos proliferativos.
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
TWI461194B (zh) 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
MX2012009830A (es) 2010-02-26 2013-02-11 Piramal Entpr Ltd Flavonas sustituidas de pirrolidina para el tratamiento de desordenes inflamatorios.
EP3399026A1 (en) 2010-06-14 2018-11-07 The Scripps Research Institute Reprogramming of cells to a new fate
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
US9776989B2 (en) 2013-04-10 2017-10-03 Council Of Scientific & Industrial Research Chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders
US9932327B2 (en) 2013-04-17 2018-04-03 The Council Of Scientific & Industrial Research Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof
CN105530931B (zh) 2013-07-12 2019-11-08 皮拉马尔企业有限公司 用于治疗黑素瘤的药物组合
HUE061672T2 (hu) 2014-11-12 2023-08-28 Seagen Inc Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
US9901574B2 (en) 2015-04-20 2018-02-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
CN111349118B (zh) * 2015-05-18 2023-08-22 住友制药肿瘤公司 具有增加的生物利用度的阿伏西地前药
CA2993659A1 (en) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
CN116217729A (zh) 2015-11-12 2023-06-06 思进公司 聚糖相互作用化合物及使用方法
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
MX2019007332A (es) 2016-12-19 2019-11-18 Tolero Pharmaceuticals Inc Péptidos indicadores y métodos para caracterizar sensibilidad.
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
JPWO2020213714A1 (ja) * 2019-04-18 2020-10-22

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1223690A (en) * 1967-10-17 1971-03-03 Fisons Pharmaceuticals Ltd Substituted chromon-2-carboxylic acids
DE2731566A1 (de) * 1977-07-13 1979-02-01 Bayer Ag Verfahren zur herstellung von neuen chromon-derivaten, sowie ihre verwendung als pflanzenschutzmittel
GB2101115A (en) * 1980-10-23 1983-01-12 Pfizer Ltd Thromboxane synthetase inhibitors
DE3311005A1 (de) * 1983-03-25 1984-09-27 Bayer Ag, 5090 Leverkusen Chromon- und thiochromonsubstituierte 1,4-dihydropyridinderivate, mehrere verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE3329186A1 (de) * 1983-08-12 1985-02-21 Hoechst Ag, 6230 Frankfurt Chromonalkaloid, verfahren zu seiner isolierung aus dysoxylum binectariferum, und seine verwendung als arzneimittel
DE3445852A1 (de) * 1984-12-15 1986-06-19 Bayer Ag, 5090 Leverkusen Dihydropyridin-carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln

Also Published As

Publication number Publication date
PT84654A (de) 1987-05-01
HK1006021A1 (en) 1999-02-05
AU7139787A (en) 1987-10-15
US4900727A (en) 1990-02-13
CA1332238C (en) 1994-10-04
KR950009861B1 (en) 1995-08-29
EP0241003B1 (de) 1993-10-06
DK185287D0 (da) 1987-04-10
ATA260587A (de) 1989-07-15
IL82149A0 (en) 1987-10-30
ES2060582T3 (es) 1994-12-01
DE3612337A1 (de) 1987-10-15
ZA872555B (en) 1987-11-25
AU602891B2 (en) 1990-11-01
JPH0686446B2 (ja) 1994-11-02
AT389875B (de) 1990-02-12
IE62244B1 (en) 1995-01-11
DK185287A (da) 1987-10-12
ATE95519T1 (de) 1993-10-15
IL82149A (en) 1994-01-25
KR870010045A (ko) 1987-11-30
PT84654B (pt) 1989-12-29
EP0241003A3 (en) 1988-10-12
DK169760B1 (da) 1995-02-20
JPS62242680A (ja) 1987-10-23
DE3787661D1 (de) 1993-11-11
IE870941L (en) 1987-10-11
EP0241003A2 (de) 1987-10-14

Similar Documents

Publication Publication Date Title
IN164232B (ja)
SE7605361L (sv) Sett att framstella nya n-substituerade fenylpiperazinderivat
GB2081264B (en) 5,10-dihydro-11h-dibenzo(b,e)(1,4)-diazepine-11-ones
ES8308543A1 (es) "procedimiento para la preparacion de nuevas 2-fenil-2-(piridiloxi)-etilaminas sustituidas".
ES465225A1 (es) Procedimiento para la preparacion de n-cicloalcohilmetil-2- fenilamino-imidazolinas-(2).
ES539160A0 (es) Un procedimiento para preparar derivados de penem
ES471688A1 (es) Procedimiento para la obtencion de derivados benz-aciloben- zimidazol-2-carboxilicos.
GR3024928T3 (en) Hydroxymethyl furazane carboxylic acid derivatives and their use in the treatment of cardio-vascular conditions
ATE30588T1 (de) Benzofuranderivate, ihre herstellung und ihre therapeutische verwendung.
IL72681A (en) 4-alkyl-5-haloimidazole-1-carboxylic acid esters and amides,their preparation and their use as nitrification inhibitors
ATE22289T1 (de) N-(3-trifluormethylphenyl)-n'-propargylpiperazi , seine herstellung und verwendung.
ES448696A1 (es) Procedimiento para la preparacion de 4-fenil-imidazolinas sustituidas.
IE802690L (en) Substituted 2-phenylamino-imidazolines-(2)
ES8303414A1 (es) Un procedimiento de preparacion de derivados de triazoloqui-nazolinona.
PT78667B (en) Chemical compounds
ES489925A1 (es) Procedimiento para la preparacion de n,n'-difenil-monohidra-zida de acido 2-(3-metil-3-butenil)-malonico